Aclaris Therapeutics (ACRS) vs Kamada (KMDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Kamada (KMDA) over the past year, gaining 99.5% versus a gain of 18.6%. Over five years, KMDA leads with a +49.7% price change compared with -79.8% for ACRS. Aclaris Therapeutics is the larger company by market cap ($557.9 million vs $448.7 million), about 1.2 times the size.
Kamada pays a dividend yielding 3.22%, while Aclaris Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | KMDA |
|---|---|---|
| Share price | $3.79 | $7.78 |
| Market cap | $557.88M | $448.70M |
| 1-day change | +11.47% | -1.46% |
| YTD return | +25.91% | +11.76% |
| 1-year return | +99.47% | +18.65% |
| 5-year return | -79.77% | +49.72% |
| P/E ratio (TTM) | — | 20.46 |
| Forward P/E | — | 13.48 |
| EPS (TTM) | $-0.58 | $0.38 |
| Dividend yield | 0.00% | 3.22% |
| Annual dividend | $0.00 | $0.25 |
| 52-week high | $6.60 | $9.35 |
| 52-week low | $1.74 | $6.55 |
| Distance from 52-week high | -42.58% | -16.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +168.60% | +73.63% |
| Average volume | 2.48M | 118.04K |
| Shares outstanding | 147.20M | 57.71M |
| Employees | 69 | 462 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed KMDA by 80.8 percentage points over the past year.
- Kamada offers a meaningfully higher dividend yield (3.22% vs 0.00%).
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Kamada
KMDA stock →Kamada Ltd. manufactures and sells plasma-derived protein therapeutics.
Health Care · Biotechnology: Pharmaceutical Preparations · 462 employees
ACRS vs KMDA FAQ
Which is bigger, Aclaris Therapeutics or Kamada?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $557.88M compared with $448.70M for Kamada (KMDA).
Which stock has performed better over the past year, ACRS or KMDA?
ACRS returned +99.47% over the past 12 months, compared with +18.65% for KMDA (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Aclaris Therapeutics or Kamada?
Kamada pays a dividend yielding 3.22%, while Aclaris Therapeutics does not currently pay a regular dividend.
Are Aclaris Therapeutics and Kamada in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.